Meeting ReportOncology: Clinical Therapy and Diagnosis
Role of 3-phase bone scintigraphy [[Unsupported ANSI Character - ]]• FDG-PET to monitor hyperbaric oxygen therapy for several types of refractory osteomyelitis.
Kenichiro Sakata, Takuya Asaka, Noritaka Ohga, Jun Sato, Kenji Hirata, Yuji Kuge, Tohru Shiga and Yoshimasa Kitagawa
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1266;
Kenichiro Sakata
3Oral Diagnosis and medicine, Graduate School of Dental Medicine Hokkaido University Sapporo Japan
Takuya Asaka
3Oral Diagnosis and medicine, Graduate School of Dental Medicine Hokkaido University Sapporo Japan
Noritaka Ohga
3Oral Diagnosis and medicine, Graduate School of Dental Medicine Hokkaido University Sapporo Japan
Jun Sato
3Oral Diagnosis and medicine, Graduate School of Dental Medicine Hokkaido University Sapporo Japan
Kenji Hirata
2Nuclear Medicine, Graduate School of Medicine Hokkaido University Sapporo Japan
Yuji Kuge
1Central Institute of Isotope Science Hokkaido University Sapporo Japan
Tohru Shiga
2Nuclear Medicine, Graduate School of Medicine Hokkaido University Sapporo Japan
Yoshimasa Kitagawa
3Oral Diagnosis and medicine, Graduate School of Dental Medicine Hokkaido University Sapporo Japan

Article Figures & Data
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
Role of 3-phase bone scintigraphy [[Unsupported ANSI Character - ]]• FDG-PET to monitor hyperbaric oxygen therapy for several types of refractory osteomyelitis.
Kenichiro Sakata, Takuya Asaka, Noritaka Ohga, Jun Sato, Kenji Hirata, Yuji Kuge, Tohru Shiga, Yoshimasa Kitagawa
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1266;
Role of 3-phase bone scintigraphy [[Unsupported ANSI Character - ]]• FDG-PET to monitor hyperbaric oxygen therapy for several types of refractory osteomyelitis.
Kenichiro Sakata, Takuya Asaka, Noritaka Ohga, Jun Sato, Kenji Hirata, Yuji Kuge, Tohru Shiga, Yoshimasa Kitagawa
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1266;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK
- SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
- Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
- Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
- NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy